Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.

OBJECTIVES: This systematic review and meta-analysis compared effects of different antibiotics on mortality in patients with bloodstream infections caused by Enterobacteriaceae with chromosomal AmpC ß-lactamase. METHODS: Databases were systematically searched for studies reporting mortality in patie...

Full description

Bibliographic Details
Main Authors: Harris, P., Wei, J., Shen, A., Abdile, A., Paynter, S., Huxley, Rachel, Pandeya, N., Doi, Y., Huh, K., O'Neal, C., Talbot, T., Paterson, D.
Format: Journal Article
Published: 2016
Online Access:http://hdl.handle.net/20.500.11937/11647
_version_ 1848747862106570752
author Harris, P.
Wei, J.
Shen, A.
Abdile, A.
Paynter, S.
Huxley, Rachel
Pandeya, N.
Doi, Y.
Huh, K.
O'Neal, C.
Talbot, T.
Paterson, D.
author_facet Harris, P.
Wei, J.
Shen, A.
Abdile, A.
Paynter, S.
Huxley, Rachel
Pandeya, N.
Doi, Y.
Huh, K.
O'Neal, C.
Talbot, T.
Paterson, D.
author_sort Harris, P.
building Curtin Institutional Repository
collection Online Access
description OBJECTIVES: This systematic review and meta-analysis compared effects of different antibiotics on mortality in patients with bloodstream infections caused by Enterobacteriaceae with chromosomal AmpC ß-lactamase. METHODS: Databases were systematically searched for studies reporting mortality in patients with bloodstream infections caused by AmpC producers treated with carbapenems, broad-spectrum ß-lactam/ß-lactamase inhibitors (BLBLIs), quinolones or cefepime. Pooled ORs for mortality were calculated for cases that received monotherapy with these agents versus carbapenems. REGISTRATION: PROSPERO international prospective register of systematic reviews (CRD42014014992; 18 November 2014). RESULTS: Eleven observational studies were included. Random-effects meta-analysis was performed on studies reporting empirical and definitive monotherapy. In unadjusted analyses, no significant difference in mortality was found between BLBLIs versus carbapenems used for definitive therapy (OR 0.87, 95% CI 0.32-2.36) or empirical therapy (OR 0.48; 95% CI 0.14-1.60) or cefepime versus carbapenems as definitive therapy (OR 0.61; 95% CI 0.27-1.38) or empirical therapy (0.60; 95% CI 0.17-2.20). Use of a fluoroquinolone as definitive therapy was associated with a lower risk of mortality compared with carbapenems (OR 0.39; 95% CI 0.19-0.78). Three studies with patient-level data were used to adjust for potential confounders. The non-significant trends favouring non-carbapenem options in these studies were diminished after adjustment for age, sex and illness severity scores, suggestive of residual confounding. CONCLUSIONS: Despite limitations of available data, there was no strong evidence to suggest that BLBLIs, quinolones or cefepime were inferior to carbapenems. The reduced risk of mortality observed with quinolone use may reflect less serious illness in patients, rather than superiority over carbapenems.
first_indexed 2025-11-14T06:55:53Z
format Journal Article
id curtin-20.500.11937-11647
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T06:55:53Z
publishDate 2016
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-116472019-02-19T04:26:53Z Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. Harris, P. Wei, J. Shen, A. Abdile, A. Paynter, S. Huxley, Rachel Pandeya, N. Doi, Y. Huh, K. O'Neal, C. Talbot, T. Paterson, D. OBJECTIVES: This systematic review and meta-analysis compared effects of different antibiotics on mortality in patients with bloodstream infections caused by Enterobacteriaceae with chromosomal AmpC ß-lactamase. METHODS: Databases were systematically searched for studies reporting mortality in patients with bloodstream infections caused by AmpC producers treated with carbapenems, broad-spectrum ß-lactam/ß-lactamase inhibitors (BLBLIs), quinolones or cefepime. Pooled ORs for mortality were calculated for cases that received monotherapy with these agents versus carbapenems. REGISTRATION: PROSPERO international prospective register of systematic reviews (CRD42014014992; 18 November 2014). RESULTS: Eleven observational studies were included. Random-effects meta-analysis was performed on studies reporting empirical and definitive monotherapy. In unadjusted analyses, no significant difference in mortality was found between BLBLIs versus carbapenems used for definitive therapy (OR 0.87, 95% CI 0.32-2.36) or empirical therapy (OR 0.48; 95% CI 0.14-1.60) or cefepime versus carbapenems as definitive therapy (OR 0.61; 95% CI 0.27-1.38) or empirical therapy (0.60; 95% CI 0.17-2.20). Use of a fluoroquinolone as definitive therapy was associated with a lower risk of mortality compared with carbapenems (OR 0.39; 95% CI 0.19-0.78). Three studies with patient-level data were used to adjust for potential confounders. The non-significant trends favouring non-carbapenem options in these studies were diminished after adjustment for age, sex and illness severity scores, suggestive of residual confounding. CONCLUSIONS: Despite limitations of available data, there was no strong evidence to suggest that BLBLIs, quinolones or cefepime were inferior to carbapenems. The reduced risk of mortality observed with quinolone use may reflect less serious illness in patients, rather than superiority over carbapenems. 2016 Journal Article http://hdl.handle.net/20.500.11937/11647 10.1093/jac/dkv346 unknown
spellingShingle Harris, P.
Wei, J.
Shen, A.
Abdile, A.
Paynter, S.
Huxley, Rachel
Pandeya, N.
Doi, Y.
Huh, K.
O'Neal, C.
Talbot, T.
Paterson, D.
Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.
title Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.
title_full Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.
title_fullStr Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.
title_full_unstemmed Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.
title_short Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.
title_sort carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by enterobacter, citrobacter or serratia species: a systematic review with meta-analysis.
url http://hdl.handle.net/20.500.11937/11647